{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progression Free"},{"measurements":[{"groupId":"OG000","value":"22"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Not Evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"To evaluate response rates with the combination of rituximab and MPV as induction chemotherapy.","groups":[{"description":"Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending. Participants will be off study at the time of death.","id":"OG000","title":"Newly Diagnosed Primary CBS Lymphoma/PCNSL"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"after 10 weeks (5 cycles)","title":"Overall Response Rates","type":"SECONDARY","unitOfMeasure":"Participants"}